

Contents

Foreword	xi
Preface	xiii
Acknowledgements	xv
Abbreviations	xvii
1 Epidemiological considerations	1
Demographics	1
Gender	1
Age	4
Increasing mortality	7
Geographic distribution	9
Disease duration, prognosis and life expectancy	9
Risk factors for developing ALS	14
The epidemiology of the Cu/Zn-SOD gene mutations	23
When was ALS first recognized?	27
Summary	29
2 The clinical spectrum of ALS	31
Diagnostic criteria	31
Clinical presentation of ALS	34
Lathyrism	37
Konzo	38
ALS commencing as a lower motoneuron syndrome	39
Particular patterns of clinical onset and their diagnosis	42
Accuracy of diagnosis of ALS	64
Summary	65

viii	<i>Contents</i>	
3	The pathology of ALS	66
	Introduction	66
	Microscopic findings in ALS	68
	ALS pathology outside the central nervous system	90
	Anatomical issues	92
	Summary	104
4	Pathogenic mechanisms in ALS	106
	Introduction	106
	Guamanian ALS	107
	Familial ALS	109
	Sporadic ALS	114
	Summary	141
5	The role of clinical neurophysiology in ALS	144
	Conduction studies in ALS	144
	Needle EMG abnormalities in ALS	148
	Fasciculation in ALS	151
	Examination of specific muscles in ALS	158
	Motor unit estimates	160
	The upper motoneuron and use of magnetic stimulation in ALS	163
	The corticomotoneuronal hypothesis of ALS	164
	Central motor conduction in ALS	166
	Excitability of the motor cortex in ALS	167
	Single unit recordings in humans using TMS	171
	Summary	188
6	The application of imaging techniques	190
	Magnetic resonance imaging	191
	Magnetic resonance spectroscopy	198
	SPECT scanning	202
	Positron emission tomography	203
	Summary	207
7	ALS therapy, therapeutic trials, and neuroprotection	209
	Trial design – placebo controls in ALS	210
	Designing clinical trials for ALS	212
	Neuroprotective therapy	215
	Glutamate excitotoxicity and antiglutamate therapy	219
	Modulation of presynaptic glutamatergic mechanisms	220

<i>Contents</i>	ix
Non-NMDA receptor-mediated neurotoxicity	222
Therapeutic agents that may act on glutamate metabolism	223
Agents acting on glutamate receptors	224
Therapy with immunosuppressants	225
Aspirin and other non-steroidal anti-inflammatory drugs	225
Neurotrophic factors	226
Therapy combining two or more neurotrophic factors	230
Calcium channel blockade	231
Symptomatic measures in ALS	231
Future therapeutic directions	235
Summary	237
8 The overlap syndromes	238
Dementia and ALS	239
Rapidly progressive dementia, CJD and ALS	243
Disinhibition–dementia–Parkinson–amyotrophy complex	245
Other cognitive changes in ALS	246
Subclinical Parkinsonism	247
Parkinsonism in ALS	248
Dementia, Parkinsonism and ALS	249
Dementia and PD in family members of patients with ALS	252
Overlap of AD, PD and ALS in relation to neuronal ageing	254
Summary	258
References	260
Index	294